Evidence map›Paper›PMID 38281009›Full record

ArticleArthritis research & therapy2024

Apolipoproteins and the risk of giant cell arteritis-a nested case-control study.

Karin Wadström, Lennart T H Jacobsson, Aladdin J Mohammad, Kenneth J Warrington, Eric L Matteson, Carl Turesson

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Karin WadströmRheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, 205 02, Sweden.
Lennart T H JacobssonRheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, 205 02, Sweden.
Aladdin J MohammadRheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.
Kenneth J WarringtonDivision of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Eric L MattesonDivision of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Carl TuressonRheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, 205 02, Sweden. Carl.Turesson@med.lu.se.
Malmö University · SEMayo Clinic in Arizona · USCenter for Rheumatology · USUniversity of Cambridge · GB

Funding

Medicinska Fakulteten, Lunds Universitet ALFSKANE-446501Reumatikerförbundet R-664091Stiftelsen Konung Gustaf V:s 80-årsfond FAI-2020-0729
6 · The paper itself

Abstract

backgroundThe etiology of giant cell arteritis (GCA) and its predictors are incompletely understood. Previous studies have indicated reduced risk of future development of GCA in individuals with obesity and/or diabetes mellitus. There is limited information on blood lipids before the onset of GCA. The objective of the study was to investigate the relation between apolipoprotein levels and future diagnosis of GCA in a nested case-control analysis.

methodsIndividuals who developed GCA after inclusion in a population-based health survey (the Malmö Diet Cancer Study; N = 30,447) were identified by linking the health survey database to the local patient administrative register and the national patient register. A structured review of medical records was performed. Four controls for every validated case, matched for sex, year of birth, and year of screening, were selected from the database. Anthropometric measures, self-reported physical activity, based on a comprehensive, validated questionnaire, and non-fasting blood samples had been obtained at health survey screening. Concentrations of apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB) in stored serum were measured using an immunonephelometric assay. Potential predictors of GCA were examined in conditional logistic regression models.

resultsThere were 100 cases with a confirmed clinical diagnosis of GCA (81% female; mean age at diagnosis 73.6 years). The median time from screening to diagnosis was 12 years (range 0.3-19.1). The cases had significantly higher ApoA-I at baseline screening compared to controls (mean 168.7 vs 160.9 mg/dL, odds ratio [OR] 1.57 per standard deviation (SD); 95% confidence interval [CI] 1.18-2.10) (SD 25.5 mg/dL). ApoB levels were similar between cases and controls (mean 109.3 vs 110.4 mg/dL, OR 0.99 per SD; 95% CI 0.74-1.32) (SD 27.1 mg/dL). The ApoB/ApoA1 ratio tended to be lower in cases than in controls, but the difference did not reach significance. The association between ApoA-I and GCA development remained significant in analysis adjusted for body mass index and physical activity (OR 1.48 per SD; 95% CI 1.09-1.99).

conclusionSubsequent development of GCA was associated with significantly higher levels of ApoA-I. These findings suggest that a metabolic profile associated with lower risk of cardiovascular disease may predispose to GCA.

Indexed as

Giant Cell ArteritisAgedApolipoprotein A-IApolipoproteinsApolipoproteins BCase-Control StudiesFemaleHumansMaleRisk FactorsApolipoprotein A-IApolipoproteinsApolipoproteins BApolipoproteinsGiant cell arteritisLipidsRisk factors

Identifiers

PMID38281009
PMCPMC10821258
OpenAlexW4391282804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.